Kidney Cancer

"Observed efficacy of pembrolizumab plus lenvatinib were confirmatory of prior observations for this combination," said Cristina Suarez Rodriguez, MD, PhD.

Data from the ARC-20 trial show promising efficacy and a manageable safety profile for casdatifan monotherapy.

Here’s a look back at notable news between July and September 2025.

This clearance adds onto a previous indication for the BioTraceIO platform in liver tumor ablation.

The combination also yielded durable responses in a subset of patients with sporadic papillary renal cell carcinoma.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Five-year data from the phase 3 KEYNOTE-426 trial confirm the clinical benefits of front-line pembrolizumab plus axitinib in advanced ccRCC.

MRWS was shown to prolong the time off systemic therapy and was associated with favorable tolerability.

A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.

Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.

The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.

ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

The approvals are supported by findings from the phase 3 CheckMate-67T trial.

"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.

"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.

"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.

A recap of the FDA submissions and regulatory decisions in urology from March 2025.

The European Commission must issue a decision on the application on or by June 2, 2025.

The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma.

"The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.